CD8+ intratumoural and stromal lymphocytic infiltrate and PD-L1 staining assessed by IHC in DDIR-positive and DDIR-negative tumours
| DDIR positive (n=24) | DDIR negative (n=102) | P value | |||
| N | % | N | % | ||
| Intratumoural | |||||
| PD-L1 | |||||
| ≥1% | 7 | 29.2 | 10 | 9.8 | 0.02 |
| <1% | 17 | 70.8 | 92 | 90.2 | |
| ≥5% | 3 | 12.5 | 2 | 2 | 0.047 |
| <5% | 21 | 70.8 | 100 | 90.2 | |
| CD8+ | |||||
| 3 | 1 | 4.2 | 0 | 0 | <0.001 |
| 2 | 4 | 16.7 | 1 | 1 | |
| 1 | 14 | 13.7 | 63 | 61.7 | |
| 0 | 5 | 4.9 | 38 | 37.2 | |
| Stromal | |||||
| PD-L1 | |||||
| ≥1% | 17 | 70.8 | 52 | 51 | 0.11 |
| <1% | 7 | 29.2 | 50 | 49 | |
| ≥5% | 8 | 33.3 | 12 | 11.8 | 0.025 |
| <5% | 16 | 66.7 | 90 | 88.2 | |
| CD8+ | |||||
| 3 | 8 | 33.3 | 10 | 9.8 | 0.026 |
| 2 | 8 | 33.3 | 45 | 44.1 | |
| 1 | 8 | 33.3 | 44 | 43.1 | |
| 0 | 0 | 0 | 3 | 2.9 | |
DDIR, DNA damage immune response; PD-L1, programmed death ligand 1.